Biotricity (OTCMKTS:BTCY) & Cerus (NASDAQ:CERS) Head-To-Head Review

Cerus (NASDAQ:CERS) and Biotricity (OTCMKTS:BTCY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Valuation & Earnings

This table compares Cerus and Biotricity’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$169.98 million	2.37	-$37.49 million	($0.17)	-12.82
Biotricity	$12.06 million	0.86	-$18.66 million	($1.32)	-0.36

Biotricity has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Cerus has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Institutional & Insider Ownership

78.4% of Cerus shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 3.4% of Cerus shares are held by insiders. Comparatively, 10.0% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Cerus and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cerus	-14.15%	-44.14%	-11.37%
Biotricity	-163.11%	N/A	-252.90%

Analyst Recommendations

This is a summary of recent ratings for Cerus and Biotricity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	0	1	2	0	2.67
Biotricity	0	0	0	0	N/A

Cerus presently has a consensus price target of $3.83, indicating a potential upside of 75.84%. Given Cerus’ higher possible upside, research analysts plainly believe Cerus is more favorable than Biotricity.

Summary

Cerus beats Biotricity on 8 of the 13 factors compared between the two stocks.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.